New batch of replacement medicines approved for use in Australia to combat ongoing medicines shortages
The Therapeutic Goods Administration (TGA) has announced some new updates to the list of Section 19A approvals to import and supply medicines to address medicine shortages.
Among the latest additions are new products approved to alleviate the ongoing shortages of sertraline hydrochloride.
Sertraline 100mg tablets, USP (Cipla), supplied by Medsurge Healthcare, has been approved till 30 June 2021 due to the following medicines being in short supply/unavailable
- Apo-Sertraline sertraline (as hydrochloride) 100 mg tablet blister pack
- Sertraline Sandoz sertraline (as hydrochloride) 100 mg flim coated tablet blister pack
- Eleva 100 sertraline (as hydrochloride) 100 mg tablet blister pack – ARTG 95583
Meanwhile, Sertraline 50mg tablets have also been approved till 30 June due to the shortage of Apo-Sertraline sertraline (as hydrochloride) 50 mg tablet blister pack.
The Sertraline products currently in the Medicine Shortages database are expected to become available again during the year. They are listed as being unavailable or in short supply for a number of reasons included: commercial changes, sudden increase in demand and manufacturing issues.
Emtricitabine/Tenofovir disoproxil Teva 200 mg/245 mg Film-coated Tablets (TEVA UK Ltd) have been granted Section 19 approval till 28 February due to the unavailability of the Tenofovir Disoproxil Emtricitabine Mylan 300/200 tenofovir disoproxil maleate 300 mg and emtricitabine 200 mg film coated tablet bottle.
The latter is currently listed as being unavailable till 31 January 2021.